Compare XMAX & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMAX | PRTA |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | Ireland |
| Employees | 22 | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.8M | 526.7M |
| IPO Year | N/A | 2013 |
| Metric | XMAX | PRTA |
|---|---|---|
| Price | $8.78 | $8.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 790.1K | 541.5K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.53 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.10 | $7.40 |
| 52 Week High | $9.31 | $11.80 |
| Indicator | XMAX | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.50 | 38.36 |
| Support Level | $8.33 | $8.12 |
| Resistance Level | $9.31 | $10.29 |
| Average True Range (ATR) | 0.21 | 0.39 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 66.99 | 21.68 |
XMax Inc is a designer and lifestyle furniture company. The company is a designer and distributor of contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. The company plans expansion into artificial intelligence (AI) while continuing to operate and develop its existing furniture business.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.